We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Editorial Comment on Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second‐line treatment with tyrosine kinase inhibitor following first‐line immune‐oncology combination therapy.
- Authors
Ishihara, Hiroki; Takagi, Toshio
- Abstract
The article discusses the treatment paradigm for patients with metastatic renal cell carcinoma (RCC) and the challenges in determining second-line subsequent therapy. The study by Matsushita et al. examines the efficacy and safety of second-line tyrosine kinase inhibitor (TKI) therapy following first-line immune-oncology combination therapies. The most commonly used second-line agent is axitinib, followed by cabozantinib, pazopanib, and sunitinib. The study reports objective response rates, disease control rates, progression-free survival, and overall survival periods for these therapies. The article emphasizes the need for further clinical results to make informed decisions about personalized subsequent therapy for metastatic RCC.
- Subjects
PROTEIN-tyrosine kinase inhibitors; EDITORIAL writing; RENAL cell carcinoma; TREATMENT effectiveness; METASTASIS; CLINICAL trials; SORAFENIB
- Publication
International Journal of Urology, 2024, Vol 31, Issue 5, p534
- ISSN
0919-8172
- Publication type
Article
- DOI
10.1111/iju.15413